UY31895A - Derivados de azacarbolinas, su preparación y su utilización terapéutica. - Google Patents

Derivados de azacarbolinas, su preparación y su utilización terapéutica.

Info

Publication number
UY31895A
UY31895A UY0001031895A UY31895A UY31895A UY 31895 A UY31895 A UY 31895A UY 0001031895 A UY0001031895 A UY 0001031895A UY 31895 A UY31895 A UY 31895A UY 31895 A UY31895 A UY 31895A
Authority
UY
Uruguay
Prior art keywords
derivatives
cancers
involved
act
development
Prior art date
Application number
UY0001031895A
Other languages
English (en)
Inventor
Babin Didier
Gouyon Thierry
Christopher Arendt
Olivier Bedel
Mikhail Levit
Serge Mignane
Neil Moorcroft
David Papin
Li Ronghua
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY31895A publication Critical patent/UY31895A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

Nuevas azacarbolinas, derivados de a(alfa)-aza-B(beta)-carbolinas de fórmula (I) en el estado de base o de sal de adición a un ácido y sus procedimientos de síntesis, útiles para el tratamiento del cáncer; en particular las que actúan sobre las proteínas quinasa del tipo CHK1, CDK1, CDK2, dyrk2, Flt3, GSK3 beta, MNK2, PDGRbeta, PIM1, PIM2, PIM3, PLK, TrkB, todas implicadas en el desarrollo de los cánceres y más particularmente, las que actúan sobre una diana denominada Pim implicada en el desarrollo de los cánceres.
UY0001031895A 2008-06-12 2009-06-12 Derivados de azacarbolinas, su preparación y su utilización terapéutica. UY31895A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0803262 2008-06-12

Publications (1)

Publication Number Publication Date
UY31895A true UY31895A (es) 2010-01-29

Family

ID=40445526

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001031895A UY31895A (es) 2008-06-12 2009-06-12 Derivados de azacarbolinas, su preparación y su utilización terapéutica.

Country Status (26)

Country Link
US (1) US20110178053A1 (es)
EP (1) EP2303882A2 (es)
JP (1) JP2011522867A (es)
KR (1) KR20110016998A (es)
CN (1) CN102124007A (es)
AR (1) AR072084A1 (es)
AU (1) AU2009259114B2 (es)
BR (1) BRPI0915204A2 (es)
CA (1) CA2725093A1 (es)
CO (1) CO6280536A2 (es)
CR (1) CR11814A (es)
DO (1) DOP2010000366A (es)
EA (1) EA018945B1 (es)
EC (1) ECSP10010670A (es)
IL (1) IL209840A0 (es)
MA (1) MA32460B1 (es)
MX (1) MX2010013699A (es)
NI (1) NI201000210A (es)
NZ (1) NZ589839A (es)
PE (1) PE20110122A1 (es)
SV (1) SV2010003754A (es)
TW (1) TW201002711A (es)
UA (1) UA101668C2 (es)
UY (1) UY31895A (es)
WO (1) WO2009150381A2 (es)
ZA (1) ZA201008387B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2515972C2 (ru) 2008-06-11 2014-05-20 Дженентек, Инк. Диазакарбазолы и способы применения
JP5658662B2 (ja) 2008-06-12 2015-01-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ ヒスタミンｈ４受容体のジアミノピリジン、ピリミジン、及びピリダジンモジュレーター
FR2950891B1 (fr) * 2009-10-06 2012-11-09 Sanofi Aventis Derives d'azacarbolines 9h-pyrrolo[2,3-b:5,4-c']dipyridine, leur preparation et leur utilisation therapeutique
EP2411389A2 (fr) * 2009-03-24 2012-02-01 Sanofi DERIVES D'AZACARBOLINES 9H-PYRROLO[2,3-b:5,4-c']DIPYRIDINE, LEUR PREPARATION ET LEUR UTILISATION THERAPEUTIQUE
FR2953838B1 (fr) * 2009-12-10 2012-02-24 Sanofi Aventis Derives de 9h-beta-carboline (ou 9h-pyridino[3,4-b]indole) trisubstitues, leur preparation et leur utilisation therapeutique
US20110183938A1 (en) * 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
CA2903463A1 (en) * 2013-03-11 2014-10-09 The Regents Of The University Of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
KR101612179B1 (ko) * 2013-04-19 2016-04-12 영남대학교 산학협력단 아미도피리딘올 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물
CN103408573B (zh) * 2013-07-12 2015-12-23 上海工程技术大学 硼酸衍生物及其制备方法和应用
WO2018137655A1 (zh) * 2017-01-25 2018-08-02 江苏豪森药业集团有限公司 吡咯并吡啶类n-氧化衍生物及其制备方法和应用
BR112020002674A2 (pt) * 2017-08-07 2020-07-28 Joint Stock Company Biocad compostos heterocíclicos inovadores como inibidores de cdk8/19
WO2020072675A1 (en) 2018-10-02 2020-04-09 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
RU2515972C2 (ru) * 2008-06-11 2014-05-20 Дженентек, Инк. Диазакарбазолы и способы применения

Also Published As

Publication number Publication date
SV2010003754A (es) 2011-03-15
ZA201008387B (en) 2012-02-29
UA101668C2 (ru) 2013-04-25
EA201170002A1 (ru) 2011-08-30
CR11814A (es) 2011-01-10
MX2010013699A (es) 2011-02-23
WO2009150381A2 (fr) 2009-12-17
CA2725093A1 (fr) 2009-12-17
JP2011522867A (ja) 2011-08-04
PE20110122A1 (es) 2011-03-07
ECSP10010670A (es) 2011-01-31
EP2303882A2 (fr) 2011-04-06
NI201000210A (es) 2011-05-09
AU2009259114B2 (en) 2013-05-23
CO6280536A2 (es) 2011-05-20
NZ589839A (en) 2012-07-27
WO2009150381A3 (fr) 2010-02-18
KR20110016998A (ko) 2011-02-18
IL209840A0 (en) 2011-02-28
BRPI0915204A2 (pt) 2019-01-15
US20110178053A1 (en) 2011-07-21
MA32460B1 (fr) 2011-07-03
EA018945B1 (ru) 2013-11-29
AR072084A1 (es) 2010-08-04
DOP2010000366A (es) 2010-12-31
TW201002711A (en) 2010-01-16
CN102124007A (zh) 2011-07-13
AU2009259114A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
UY31895A (es) Derivados de azacarbolinas, su preparación y su utilización terapéutica.
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
BRPI1004899B8 (pt) composto inibidor de fosfoinositida 3-quinase, composição farmacêutica e uso de um composto
ECSP109934A (es) Compuesto - 946
CR20160203A (es) Inhibidores de tirosina cinasa de bruton
CO6670585A2 (es) Promotores de apotosis n-acilsufonamidas
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
DOP2010000011A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
UY32605A (es) Agentes antiinflamatorios como compuestos virostáticos
CU20110145A7 (es) Derivados de sulfonamida
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
SV2011003939A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
ECSP12011720A (es) Compuestos heterocíclicos y usos de los mismos
UY30559A1 (es) Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
ECSP088747A (es) Pirazoles como inhibidores de la 11-beta-hsd1
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
CL2008003873A1 (es) Compuestos derivados de benzofuropirimidinona sustituidos, inhibidores de proteinas quinasas; composicion farmaceutica que comprende a uno de los compuestos; metodo para inhibir in vitro proteinas quinasa (pim, cdc7,ck2); y uso de los compuestos en la preparacion de medicamentos para el tratamiento del cancer
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
AR078613A1 (es) Derivados de sulfoxidos benzooxazolicos y benzotriazolicos inhibidores de autotaxinas, medicamentos que los contienen y uso de los mismos para el tratamiento de tumores.
UY30298A1 (es) Inhibidores de la quinasa c-fms ii
AR092219A1 (es) Conjugados anticuerpo-farmaco (adc) que se unen a proteinas 158p1d7

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140602